Most peptides require a pin and a bit of courage to use. 5-Amino-1MQ does not. You swallow a capsule in the morning and move on with your day. That convenience is not an accident. The compound was designed for oral delivery because its chemical structure makes it highly bioavailable in capsule form. But is this actually worth taking?
That is the right question to ask before you buy anything. Here is what the evidence actually shows.
What 5-Amino-1MQ Does Differently
5-Amino-1MQ is a small molecule, not a peptide in the traditional sense. It is a quinolinium derivative, and its chemistry makes it cell-permeable and stable enough to work when swallowed.
Its actual function is NNMT inhibition. NNMT stands for nicotinamide N-methyltransferase. Your fat cells have a metabolic rate. When those cells enlarge, which is what happens when you gain weight, they start overproducing NNMT. NNMT is an enzyme that converts nicotinamide (a form of vitamin B3) into a waste byproduct. That conversion removes nicotinamide from the NAD+ salvage pathway. Less nicotinamide available means lower NAD+ levels. Lower NAD+ means slower cellular metabolism in fat tissue.
This creates a self-reinforcing loop. More fat leads to more NNMT, which slows fat metabolism, which leads to more fat accumulation. NNMT also drives inflammatory signals that worsen metabolic dysfunction.
5-Amino-1MQ blocks that enzyme. When NNMT is inhibited, nicotinamide gets redirected into NAD+ synthesis instead of being excreted. NAD+ levels inside fat cells rise. SIRT1 activates. SIRT1 increases fatty acid oxidation, reduces fat storage, and improves insulin sensitivity. The fat cells themselves start functioning more like they did before they became enlarged and inflamed.
Animal studies also show 5-Amino-1MQ stimulates conversion of white adipose tissue into beige adipose tissue. Beige fat burns energy rather than storing it. That is a meaningful difference from compounds that simply reduce appetite.
Why Capsules Work for This One
Most peptides cannot be taken orally. They get broken down in the gastrointestinal tract before they reach the bloodstream. 5-Amino-1MQ is different. Cell-based studies showed excellent membrane transport with no detectable efflux. Animal data confirmed significant oral bioavailability. This is one of the few compounds in the metabolic optimization space where you do not need a syringe.
No reconstitution. No refrigeration. Room temperature storage is fine. You take your capsules in the morning and move on.
The injectable form exists and some users prefer it for perceived bioavailability. There is no head-to-head human trial comparing oral versus injectable dosing. The human trial that exists used oral capsules, so that is where the most reliable human data sits.
The Human Trial Data
Here is what separates 5-Amino-1MQ from the vast majority of compounds in this space. There is actually a human trial.
A double-blind, placebo-controlled study was conducted on U.S. military veterans. The trial lasted 12 weeks. Participants received 5-Amino-1MQ orally. The results showed significant weight loss without reported adverse side effects.
This was a specific trial on a specific population. It was not a large Phase 3 efficacy trial. But it was a controlled human study with a placebo arm, and that puts this compound ahead of most things marketed in the peptide space.
The rest of the evidence is animal and cell data, and it is worth knowing.
In diet-induced obese rats, 5-Amino-1MQ produced a 6% reduction in body weight over 11 days. Lipogenesis decreased by 70%. Total cholesterol dropped 30%. Adipocyte size reduced by over 30%. Critically, food intake was identical between treated and control animals. The fat loss was metabolic, not appetite-driven.
NNMT expression is approximately 2-fold higher in the subcutaneous and abdominal adipose tissue of people with type 2 diabetes compared to healthy controls. Elevated NNMT appears to be part of the mechanism driving metabolic dysfunction, not just a correlate of it.
Body Recomposition Results: Realistic Expectations
5-Amino-1MQ is not a weight loss drug in the way that GLP-1 agonists are. You will not feel dramatically less hungry. The rat data showed identical food intake between treated and control groups.
What you are getting is a metabolic shift in how your fat cells operate. Expected outcome based on available data is gradual fat loss and improved body composition. The magnitude is likely smaller than what you would see with tirzepatide or semaglutide.
The appeal for body recomposition is specific. If you are already training, eating protein adequately, and maintaining a caloric deficit, 5-Amino-1MQ may help your body access stored fat more efficiently. Some rat data suggests enhanced muscle regeneration when combined with exercise. That is a legitimate signal, though it has not been validated in humans.
Realistic expectation: modest fat loss over 8-12 weeks when combined with diet and exercise. If you want dramatic scale drops, look at GLP-1 agonists. If you want metabolic support that does not suppress your appetite or erode your lean mass, 5-Amino-1MQ is worth knowing about.
Dosage Guide
The human trial provides the most reliable data point. That trial used oral administration over 12 weeks at the 50-150mg range. Community protocols have evolved from there.
Dosage Table
| Context | Dose | Route | Duration |
|---|---|---|---|
| Human trial | 50-150mg/day | Oral | 12 weeks |
| Starting dose | 50mg/day | Oral | Weeks 1-2 |
| Standard protocol | 100-150mg/day | Oral | Weeks 3-12 |
| Vendor capsule size | 50mg | Oral | Per capsule |
Start at 50mg daily for the first 1-2 weeks to assess tolerance. If you handle it well, increase to 100-150mg daily. Most community protocols settle at 100mg as the maintenance dose.
Ascension Peptides sells 5-Amino-1MQ in 50mg capsules. That aligns with the standard oral protocol. One capsule per day for the first two weeks, then two to three capsules per day depending on your response.
Side Effects: What We Know Versus What We Do Not
What the human trial showed: no significant adverse effects were reported at 12 weeks. The compound was generally well tolerated in the veteran population.
What animal studies showed: negligible toxicity at therapeutic doses. No liver enzyme elevations in rats at relevant doses.
What we do not know: there is no long-term human safety data. The longest human exposure is 12 weeks. There are no multi-year studies, no large-scale Phase 2 or Phase 3 trials.
Community reports describe a manageable side effect profile:
- Mild gastrointestinal discomfort in the first week, typically transient
- Slight stimulant effect, particularly early use, manifesting as increased energy
- Occasional mild headaches, usually dose-related
- Mild insomnia if taken too late in the day
The key unknown is the cancer connection. NNMT is overexpressed in several human cancers, including glioblastoma, papillary thyroid cancer, renal clear cell carcinoma, bladder cancer, gastric cancer, and colorectal cancer. Higher NNMT expression in tumor tissue is associated with lower overall survival rates.
This does not mean 5-Amino-1MQ causes cancer. The data does not support that conclusion. What it means is that if you have a personal or family history of cancer, you need a real conversation with a physician who has access to your full medical history before using this. Not a telehealth approval. An actual doctor who knows your situation.
Cycling Recommendations
The absence of long-term human safety data is the primary reason cycling exists. A common protocol is 8-12 weeks on, followed by 4-8 weeks off. This gives your system a break from a compound with limited human long-term data and helps maintain receptor sensitivity.
The off period also lets you assess whether the metabolic benefits persist or diminish. Some users report that body composition gains are partially maintained after discontinuation, which would be consistent with genuine metabolic adaptation rather than temporary appetite suppression.
No post-cycle therapy is required. 5-Amino-1MQ does not affect hormonal pathways. It does not suppress testosterone or disrupt the HPA axis.
Morning dosing is preferred to align with your natural metabolic peak. Consistent timing matters more than the exact hour.
Ascension Availability
Ascension Peptides carries 5-Amino-1MQ in 50mg capsules, currently in stock. The capsule format aligns with how the compound was studied in the human trial and how its oral bioavailability was established.
Shop 5-Amino-1MQ Capsules at Ascension Peptides
Frequently Asked Questions
Is 5-Amino-1MQ the same as NAD+ precursors like NMN or NR?
No. NAD+ precursors provide more substrate for NAD+ synthesis. 5-Amino-1MQ prevents nicotinamide from being diverted away from the NAD+ pathway. Different mechanisms. They can theoretically be used together, though combining compounds always warrants caution.
Will 5-Amino-1MQ suppress my appetite?
No. The rat studies showed identical food intake between treated and control groups. Weight loss occurred through metabolic change, not reduced food consumption. If appetite suppression is your priority, look at tirzepatide for weight loss or semaglutide.
How is this different from MK-677 capsules?
MK-677 capsules work through ghrelin receptor agonism to stimulate growth hormone release. 5-Amino-1MQ works through NNMT inhibition to shift fat cell metabolism. Different mechanisms, different side effect profiles, and different expected outcomes. MK-677 increases appetite as part of its mechanism. 5-Amino-1MQ does not affect appetite signaling.
Do I need to cycle 5-Amino-1MQ?
Yes. The standard recommendation is 8-12 weeks on, 4-8 weeks off. This accounts for the absence of long-term human safety data and helps maintain sensitivity to the compound.
Can I take 5-Amino-1MQ if I am on other medications?
Drug interaction data is limited. Theoretically, compounds affecting NAD+-dependent pathways could interact. Discuss with your physician, especially if you are on diabetes medications, blood pressure medications, or anything affecting metabolic or liver function.
Does 5-Amino-1MQ cause cancer?
NNMT is overexpressed in several human cancers. However, existing data does not establish that 5-Amino-1MQ causes cancer. What it establishes is that you should disclose any cancer history or strong family cancer history to your physician before using this. If you have active cancer or are undergoing cancer treatment, do not use this compound.
If you found this useful, explore more on metabolic optimization. I have covered tirzepatide for weight loss as a comparison point for GLP-1 agonists and how they stack against non-appetite-suppressing approaches. I have also written about MK-677 capsules in detail for those evaluating growth hormone secretagogues.
Keywords: 5 amino 1mq capsules, 5-amino-1mq dosage, 5-amino-1mq side effects, 5-amino-1mq weight loss, 5-amino-1mq review, nnmt inhibitor
